Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bellus Health Inc (BLU)

Bellus Health Inc (BLU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 495,090
  • Shares Outstanding, K 78,337
  • Annual Sales, $ 20 K
  • Annual Income, $ -31,760 K
  • 60-Month Beta 0.25
  • Price/Sales 31,439.25
  • Price/Cash Flow N/A
  • Price/Book 2.57
Trade BLU with:

Options Overview Details

View History
  • Implied Volatility 114.67%
  • Historical Volatility 92.47%
  • IV Percentile 53%
  • IV Rank 20.91%
  • IV High 365.01% on 08/06/21
  • IV Low 48.49% on 08/05/21
  • Put/Call Vol Ratio 0.10
  • Today's Volume 637
  • Volume Avg (30-Day) 2,236
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 13,168
  • Open Int (30-Day) 6,289

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.24
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.27
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -166.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.32 +92.17%
on 08/25/21
6.87 -7.13%
on 09/23/21
+2.99 (+88.20%)
since 08/24/21
3-Month
2.60 +145.38%
on 07/19/21
6.87 -7.13%
on 09/23/21
+3.08 (+93.33%)
since 06/24/21
52-Week
2.12 +200.94%
on 09/28/20
6.87 -7.13%
on 09/23/21
+4.23 (+196.74%)
since 09/24/20

Most Recent Stories

More News
BELLUS (BLU) Completes Enrollment in Two Mid-Stage Studies

BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.

REGN : 637.02 (-1.47%)
MRK : 73.48 (+0.59%)
BAYRY : 13.6800 (-0.44%)
BLU : 6.29 (-0.47%)
BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other...

BLU : 6.29 (-0.47%)
BLU.TO : 7.91 (-1.25%)
Implied Volatility Surging for BELLUS Health (BLU) Stock Options

Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.

BLU : 6.29 (-0.47%)
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

--Data from interim analysis support accelerated planning for the Phase 3 program

BLU : 6.29 (-0.47%)
BLU.TO : 7.91 (-1.25%)
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC")...

BLU : 6.29 (-0.47%)
BLU.TO : 7.91 (-1.25%)
BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other...

BLU : 6.29 (-0.47%)
BLU.TO : 7.91 (-1.25%)
New Strong Sell Stocks for May 25th

AJRD, BLU, GMBL, LITE, and PSXP have been added to the Zacks Rank #5 (Strong Sell) List on May 25, 2021

PSXP : 35.93 (+0.62%)
AJRD : 41.72 (+0.77%)
LITE : 86.65 (+1.37%)
GMBL : 7.51 (-0.79%)
BLU : 6.29 (-0.47%)
BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC")...

BLU : 6.29 (-0.47%)
BLU.TO : 7.91 (-1.25%)
New Strong Sell Stocks for May 18th

AFYA, BLU, CHRA, DHX, and EBMT have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2021

DHX : 4.62 (+2.44%)
EBMT : 21.87 (-1.00%)
CHRA : 4.48 (-0.86%)
BLU : 6.29 (-0.47%)
AFYA : 20.39 (-0.29%)
DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - May 17, 2021) - , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("BELLUS" or "the Company")...

BLU : 6.29 (-0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.

See More

Key Turning Points

3rd Resistance Point 7.50
2nd Resistance Point 7.19
1st Resistance Point 6.75
Last Price 6.29
1st Support Level 6.00
2nd Support Level 5.69
3rd Support Level 5.25

See More

52-Week High 6.87
Last Price 6.29
Fibonacci 61.8% 5.06
Fibonacci 50% 4.49
Fibonacci 38.2% 3.93
52-Week Low 2.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar